Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm³: A Post Hoc Analysis from the ANANKE Study

References

• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–373. doi:10.1183/09031936.00202013
   PubMed Web of Science ®Google Scholar
• Hekking PPW, Wener RR, Amelink M, et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135:896–902. doi:10.1016/j.jaci.2014.08.042
   PubMed Web of Science ®Google Scholar
• Perez-de-Llano L, Tran TN, Al-ahmad M, et al. Characterization of eosinophilic and non-eosinophilic severe asthma phenotypes and proportion of patients with these phenotypes in the international severe asthma registry (ISAR). Am J Respir Crit Care Med Am Thorac Soc. 2020;201:A4525.
   Web of Science ®Google Scholar
• de Groot JC, ten Brinke A, Bel EHD. Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res. 2015;1:24. doi:10.1183/23120541.00024-2015
   PubMedGoogle Scholar
• Heaney LG, Perez de Llano L, Al-Ahmad M, et al. Eosinophilic and Noneosinophilic Asthma. Chest. 2021;160:814–830. doi:10.1016/j.chest.2021.04.013
   PubMed Web of Science ®Google Scholar
• Bakakos A, Loukides S, Bakakos P. Severe Eosinophilic Asthma. J Clin Med. 2019;8:1375. doi:10.3390/jcm8091375
   PubMed Web of Science ®Google Scholar
• Sweeney J, Patterson CC, Menzies-Gow A, et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the optimum patient care research database and the British thoracic difficult asthma registry. Thorax. 2016;71:339–346. doi:10.1136/thoraxjnl-2015-207630
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Ghushchyan VH, Globe G, Schatz M. Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol. 2018;141:110–116.e7. doi:10.1016/j.jaci.2017.04.009
   PubMed Web of Science ®Google Scholar
• Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193–204. doi:10.2147/JAA.S176026
   PubMed Web of Science ®Google Scholar
• Lee H, Ryu J, Nam E, et al. Increased mortality in patients with corticosteroid-dependent asthma: a nationwide population-based study. Eur Respir J. 2019;54:1900804. doi:10.1183/13993003.00804-2019
   PubMed Web of Science ®Google Scholar
• Bourdin A, Molinari N, Vachier I, et al. Mortality: a neglected outcome in OCS-treated severe asthma. Eur Respir J. 2017;50:1701486. doi:10.1183/13993003.01486-2017
   PubMed Web of Science ®Google Scholar
• Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. N Engl J Med. 2022;386:157–171. doi:10.1056/NEJMra2032506
   PubMed Web of Science ®Google Scholar
• Dagher R, Kumar V, Copenhaver AM, et al. Novel mechanisms of action contributing to benralizumab’s potent anti-eosinophilic activity. Eur Respir J. 2022;59:2004306. doi:10.1183/13993003.04306-2020
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115–2127. doi:10.1016/S0140-6736(16)31324-1
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128–2141. doi:10.1016/S0140-6736(16)31322-8
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Menzies-Gow A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018;6:51–64. doi:10.1016/S2213-2600(17)30344-2
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Gurnell M, Heaney LG, et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med. 2022;10:47–58. doi:10.1016/S2213-2600(21)00352-0
   PubMed Web of Science ®Google Scholar
• Pelaia C, Busceti MT, Vatrella A, et al. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose. Pulm Pharmacol Ther. 2019;58:101830. doi:10.1016/j.pupt.2019.101830
   PubMed Web of Science ®Google Scholar
• Pelaia C, Busceti MT, Crimi C, et al. Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma. Biomed Pharmacother. 2020;129:110444. doi:10.1016/j.biopha.2020.110444
   PubMed Web of Science ®Google Scholar
• Nolasco S, Crimi C, Pelaia C, et al. Benralizumab effectiveness in severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: a real-world multicenter study. J Allergy Clin Immunol Pract. 2021;9:4371–4380. doi:10.1016/j.jaip.2021.08.004
   PubMed Web of Science ®Google Scholar
• Scioscia G, Carpagnano GE, Quarato CMI, et al. Effectiveness of benralizumab in improving the quality of life of severe eosinophilic asthmatic patients: our real-life experience. Front Pharmacol. 2021;12:631660. doi:10.3389/fphar.2021.631660
   PubMed Web of Science ®Google Scholar
• Pelaia C, Crimi C, Benfante A, et al. Therapeutic effects of benralizumab assessed in patients with severe eosinophilic asthma: real-life evaluation correlated with allergic and non-allergic phenotype expression. J Asthma Allergy. 2021;14:163–173. doi:10.2147/JAA.S297273
   PubMed Web of Science ®Google Scholar
• ChAracterisation of Italian severe uncontrolled asthmatic patieNts key features when receiving benralizumab (ANANKE). Available from: https://clinicaltrials.gov/ct2/show/NCT04272463. Accessed November 4, 2022.
   Google Scholar
• Menzella F, Bargagli E, Aliani M, et al. ChAracterization of Italian severe uncontrolled asthmatic patients key features when receiving benralizumab in a real-life setting: the observational rEtrospective ANANKE study. Respir Res. 2022;23:36. doi:10.1186/s12931-022-01952-8
   PubMed Web of Science ®Google Scholar
• Kraft M, Brusselle G, FitzGerald JM, et al. Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma. Eur Respir J. 2021;58:2100413. doi:10.1183/13993003.00413-2021
   PubMed Web of Science ®Google Scholar
• Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3:849–858. doi:10.1016/S2213-2600(15)00367-7
   PubMed Web of Science ®Google Scholar
• Backman H, Lindberg A, Hedman L, et al. FEV1 decline in relation to blood eosinophils and neutrophils in a population-based asthma cohort. World Allergy Organ J. 2020;13:100110. doi:10.1016/j.waojou.2020.100110
   PubMed Web of Science ®Google Scholar
• Tan WC, Bourbeau J, Nadeau G, et al. High eosinophil counts predict decline in FEV 1: results from the CanCOLD study. Eur Respir J. 2021;57:2000838. doi:10.1183/13993003.00838-2020
   PubMed Web of Science ®Google Scholar
• Bumbacea D, Campbell D, Nguyen L, et al. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J. 2004;24:122–128. doi:10.1183/09031936.04.00077803
   PubMed Web of Science ®Google Scholar
• Menzella F, Fontana M, Galeone C, et al. Real world effectiveness of benralizumab on respiratory function and asthma control. Multidiscip Respir Med. 2021;16(1):785. doi:10.4081/mrm.2021.785
   PubMed Web of Science ®Google Scholar
• Korn S, Bourdin A, Chupp G, et al. Integrated safety and efficacy among patients receiving benralizumab for up to 5 years. J Allergy Clin Immunol Pract. 2021;9:4381–4392. doi:10.1016/j.jaip.2021.07.058
   PubMed Web of Science ®Google Scholar
• Miralles López J, Andújar-Espinosa R, Bravo-Gutiérrez F, et al. Effectiveness of benralizumab in severe eosinophilic asthma under routine clinical practice. J Investig Allergy Clin Immunol. 2022;32:220–223.
   PubMed Web of Science ®Google Scholar
• Jackson DJ, Burhan H, Menzies-Gow A, et al. Benralizumab effectiveness in severe asthma is independent of previous biologic use. J Allergy Clin Immunol Pract. 2022;S2213–2198(22):141.
   Google Scholar
• Paoletti G, Di Bona D, Chu DK. Allergen immunotherapy: the growing role of observational and randomized trial “Real‐World Evidence”. Allergy. 2021;76:2663–2672. doi:10.1111/all.14773
   PubMed Web of Science ®Google Scholar